health
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
TL;DR
- GSK is in talks to acquire Nuvalent for over $9 billion.
- This would be GSK's largest acquisition in over a decade.
- The deal could be finalized as early as this week.
- Nuvalent has two key assets, neladalkib and zidesamtinib, for lung cancer currently under FDA review.
- The acquisition comes during a period of high activity in biotech dealmaking.
- The deal would represent a premium of 29% to 43% over Nuvalent's current market capitalization.